Post-mRNA COVID-19 Vaccination Myocarditis

Abhishek Matta; Rekha Kallamadi; Danielle Matta; Dinesh Bande

doi:10.12890/2021_002769

Post-mRNA COVID-19 Vaccination Myocarditis

Eur J Case Rep Intern Med. 2021 Aug 16;8(8):002769. doi: 10.12890/2021_002769. eCollection 2021.

Authors

Abhishek Matta^{1

2}, Rekha Kallamadi^{1

2}, Danielle Matta², Dinesh Bande^{1

2}

Affiliations

¹ University of North Dakota School of Medicine and Health Sciences, Grand Forks, USA.
² Sanford Health, Fargo, USA.

Abstract

A new trend of myocarditis among young adults who received mRNA vaccines for COVID-19 is emerging. We present the case of a young adult who presented with chest pain 3 days after the second dose of Pfizer-BioNTech COVID-19 vaccine. He had elevated troponin I and C-reactive protein levels at the time of admission. Electrocardiogram (ECG) and echocardiogram findings were unremarkable. The patient improved with conservative management and was discharged home the next day.

Learning points: Myocarditis is rare but is increasingly being reported in young adults post vaccination for COVID-19.Patients usually present with chest pain, elevated troponin and/or inflammatory markers.The condition carries a good prognosis and patients usually recover with supportive care.

Keywords: COVID-19; COVID-19 vaccine; myocarditis.